Resitu: minimally invasive surgical technology

Helping us establish the Resitu technology – Investors

With support from our investors, the Resitu technology has the potential to become the globally preferred method to manage breast cancer.

Based on an invention by surgeon Per Hedén

The Resitu technology for minimally invasive surgery is built on a patented invention by surgeon Per Hedén. The first product is under development and the second-generation product is planned to establish the Resitu technology as the preferred method to treat small tumours of the breast.

Preparing for launch

Resitu Medical plans to launch the first product in the EU and later in the US. The first line of products will focus on biopsy and breast tissue removal. Preclinical studies are ongoing and clinical validations are planned for CE marking of the first instrument.

Major shareholders

In 2021-2022 Resitu Medical raised seed capital to reach the final product design and to start serial production to perform clinical trials towards CE mark and FDA clearance for our first product. Our major shareholders are Novoaim (63%), ALMI Invest Stockholm (13%) and STOAF (13%).

Upcoming rounds

Seed round #3 will enable clinical validations to prepare for market entry and achieve CE mark. Series A and B rounds are planned for 2024 and 2026 to expand into additional markets and for further product development.


Resitu Medical AB
Rapsgatan 7B
Uppsala, Sweden

Resitu Medical AB is a Swedish Medical Device company founded in 2019. The company is developing instruments enabling safe removal of intact tissues by a revolutionary technology. The solution has the potential to create a paradigm shift in the management of breast cancer. The portfolio of instruments will speed up the process of cancer management using a minimally invasive approach and facilitating the way radiologists and surgeons work.

By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively.